DUBLIN, June 19, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/cf5xzs/global) has announced the addition of the "Global Non-melanoma Skin Cancer Market 2014-2018" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
A current trend witnessed in the Global Non-melanoma Skin Cancer market is the use of combination therapies for the treatment of non-melanoma skin cancer. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapies help in the complete removal of tumors and destruction of cancerous cells.
For instance, radiation therapy may be used in combination with other therapies (chemotherapy and surgery) to treat aggressive or recurrent non-melanoma skin cancer. Patients that are non-reactive may react to combination therapy with 0.5 percent tretinoin cream with 5-FU cream. Thicker hypertrophic lesions should be treated first with cryosurgery, gentle curettage, or even primed with applications of tretinoin cream or short courses of topical diclofenac sodium. The combination is chosen according to the size of the tumor and risk of recurrence.
According to the report, the Global Non-melanoma Skin Cancer market is driven by several factors, of which the increasing prevalence of non-melanoma skin cancer resulting from factors such as increased exposure to UV rays, ozone layer depletion, and genetic mutation is one of the major drivers.
Further, the report states that one of the major challenges faced by the market is the availability of alternative treatments such as surgery and non-invasive treatments. Surgery is the most preferred option for the treatment of BCC and SCC as its success rate is 99 percent. These alternative treatments limit the consumption of drugs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Market Segmentation by Type
08. Pipeline Analysis
09. Geographical Segmentation
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
18. Non-invasive Treatment Market
19. Key Vendor Analysis
20. Other Reports in this Series
Companies Mentioned:
- Almirall SA
- Aqua Pharmaceuticals LLC
- Biofrontera AG
- Boehringer Ingelheim GmbH
- Bristol Myers Squibb Co.
- Cannabis Science Inc.
- Cellceutix Corp.
- Elekta AB
- Eli Lilly and Co.
- F. Hoffmann-la Roche Ltd.
- Galderma SA
- GENEXTRA SpA
- iCAD Inc.
- IRX Therapeutics Inc.
- LEO Pharma A/S
- Meda AB
- Merck & Co. Inc.
- Moberg Pharma AB
- Mylan Pharmaceutical Inc
- Novartis International AG
- Oncothyreon Inc.
- Sun Pharma Industries Ltd.
- Valeant Pharmaceuticals Inc.
- Varian Medical Systems Inc.
For more information visit http://www.researchandmarkets.com/research/cf5xzs/global
Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
Share this article